KalVista Pharmaceuticals (NASDAQ: KALV) and Opiant Pharmaceuticals (NASDAQ:OPNT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.
This is a summary of recent recommendations for KalVista Pharmaceuticals and Opiant Pharmaceuticals, as reported by MarketBeat.com.
||Strong Buy Ratings
KalVista Pharmaceuticals currently has a consensus price target of $27.00, suggesting a potential upside of 195.40%. Given KalVista Pharmaceuticals’ higher probable upside, equities research analysts plainly believe KalVista Pharmaceuticals is more favorable than Opiant Pharmaceuticals.
This table compares KalVista Pharmaceuticals and Opiant Pharmaceuticals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Valuation & Earnings
This table compares KalVista Pharmaceuticals and Opiant Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Opiant Pharmaceuticals has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Opiant Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
76.1% of KalVista Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.7% of Opiant Pharmaceuticals shares are owned by institutional investors. 49.1% of KalVista Pharmaceuticals shares are owned by company insiders. Comparatively, 63.8% of Opiant Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Opiant Pharmaceuticals beats KalVista Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.